Vernalis PLC

Unaudited Interim Results for the six months ended 31 December 2016 - Seite 3

"We expect to achieve a number of milestones from the remainder of the cough cold franchise in 2017, including potential approvals by FDA of CCP-07 and CCP-08. We also continue to seek other opportunities to leverage our US commercial infrastructure and remain very excited about the growth potential of the business."

Presentation & Conference Call
Vernalis management will host a presentation at 9.30am (UK) today at the offices of FTI Consulting 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. It will also be available via webcast at http://www.vernalis.com/investor-centre/presentations-and-webcasts and www.cantos.com and via conference call, which can be joined by dialling: [phone], Passcode 5780976# Please contact Jack Bower at FTI consulting [phone] for details.

-- ends --

Enquiries:

Vernalis plc:	[phone]
Ian Garland, Chief Executive Officer
David Mackney, Chief Financial Officer
Canaccord Genuity Limited (Nominated Adviser and Joint Broker):	[phone]
Rupert Winckler
Henry Fitzgerald-O'Connor
Emma Gabriel
Shore Capital (Joint Broker)	[phone]
Bidhi Bhoma
Toby Gibbs
FTI Consulting (Financial Communications):	[phone]
Ben Atwell
Simon Conway
Stephanie Cuthbert

Click on, or paste the following link into your web browser, to view the associated PDF document.
 http://www.rns-pdf.londonstockexchange.com/rns/3727X_1-2017-2-20.pdf

This information is provided by RNS
The company news service from the London Stock Exchange
END

Vernalis plc:
Ian Garland, Chief Executive Officer
David Mackney, Chief Financial Officer
[phone]

Canaccord Genuity Limited (Nominated Adviser and Joint Broker):
Rupert Winckler
Henry Fitzgerald-O'Connor
Emma Gabriel
[phone]

Shore Capital (Joint Broker)
Bidhi Bhoma
Toby Gibbs
[phone]

FTI Consulting (Financial Communications):
Ben Atwell
Simon Conway
Stephanie Cuthbert
[phone]